Quantcast
Last updated on April 23, 2014 at 10:40 EDT

Latest Association for Frontotemporal Degeneration Stories

2013-09-05 12:26:05

Grassroots Fundraisers Host Events from Connecticut to California to Canada PHILADELPHIA, Sept. 5, 2013 /PRNewswire-USNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) will launch its first-ever "Food for Thought" campaign from September 29 - October 6 to raise awareness of frontotemporal degeneration (FTD). To date, 44 grassroots supporters of AFTD in 24 states and 3 Canadian provinces will host events involving food and FTD education in their hometowns in a...

2012-10-18 11:23:11

SANTA MONICA, Calif., Oct. 18, 2012 /PRNewswire/ -- An opening reception for 3 Women will take place on October 25, 2012 with a VIP art preview at 6:00 pm for donors of Save The Ta-tas Foundation and The Association for Frontotemporal Degeneration (AFTD). This is an opportunity to meet the three artists, Southern California-based photographers Cyndee Howard, Lisa Schulte and Tatiana Botton, and curator Chip Tom in person. The event opens to the public at 7:30pm. 3 Women will be open October...

2012-03-07 11:17:00

NEW YORK, March 7, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) announced today the recipients of their fifth annual research award, Frontotemporal Degeneration Drug Discovery Program. The goal of the program is to accelerate the development of novel therapies for frontotemporal degeneration (FTD). The ADDF/AFTD program awarded $300,000 to three academic scientists developing biomarkers...

2011-06-15 09:00:00

NEW YORK, June 15, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be...